Novo Nordisk not keen on any major acquisitions

In an interview with The Wall Street Journal (WSJ), Novo Nordisk’s CEO, Mr Lars Sorenson, said that the company has no plans to pursue any big acquisitions


Mr Lars Sorenson, CEO, Novo Nordisk (Photo Courtesy: Reuters)

However, the company has expressed interest in smaller licensing deals.

Mr Sorenson considers the insulin market to be big and growing fast that the company doesn't need to depend on acquisitions.

"Major acquisitions and major mergers are hugely distractive and often destructive," he told WSJ.

(News Source: The Wall Street Journal)


Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

National Health Policy

Is National Health Policy 2017 helpful for patients?

Send this article by email